Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014;9(9):1013-23.
doi: 10.2217/fmb.14.78.

Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial

Savion Gropper  1 , Nuria Albareda, Klaus Chelius, Dawie Kruger, Ismail Mitha, Yacoob Vahed, Mashra Gani, Fernando García-Alonso; Ozenoxacin in Impetigo Trial Investigators Group
Collaborators, Affiliations
Randomized Controlled Trial

Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial

Savion Gropper et al. Future Microbiol. 2014.

Abstract

Aim: We compared the efficacy and safety of ozenoxacin (a new nonfluorinated quinolone) 1% cream with placebo in the treatment of impetigo.

Patients & methods: In a randomized, double-blind, multicenter study, patients received ozenoxacin cream or placebo cream twice daily for 5 days (a third group received retapamulin 1% ointment as a control). Clinical, microbiological and laboratory evaluations were performed during follow-up (over 2 weeks).

Results: Ozenoxacin was superior to placebo (success rate 34.8 vs 19.2%; p = 0.003). Microbiological success was 70.8% for ozenoxacin and 38.2% for placebo after 3-4 days and 79.2% versus 56.6% after 6-7 days. Ozenoxacin produced more rapid microbiological clearance than retapamulin. All treatments were well tolerated.

Conclusion: Ozenoxacin 1% cream was effective and safe in the treatment of impetigo.

Keywords: Staphylococcus aureus; Streptococcus pyogenes; impetigo; ozenoxacin; retapamulin; skin infection.

PubMed Disclaimer

Publication types